^
    1m
    Utility of MEF2B immunohistochemistry in distinguishing follicular lymphoma and marginal zone lymphoma in diagnostically challenging cases. (PubMed, J Hematop)
    MEF2B immunohistochemistry can aid in distinguishing FL from MZL in diagnostically challenging cases.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6)
    1m
    Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients (clinicaltrials.gov)
    P1/2, N=91, Recruiting, Curocell Inc. | Trial completion date: Feb 2028 --> Sep 2030 | Trial primary completion date: May 2023 --> Aug 2030
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • Rimqarto (anbalcabtagene autoleucel)
    1m
    RG1716009: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, University of Washington | Trial completion date: Jan 2031 --> Jan 2028
    Trial completion date
    |
    Rituxan (rituximab) • Ninlaro (ixazomib) • Truxima (rituximab-abbs)
    1m
    BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Luminary Therapeutics
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    1m
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov)
    P1, N=16, Completed, Acepodia Biotech, Inc. | Active, not recruiting --> Completed | N=42 --> 16 | Trial completion date: Sep 2027 --> Mar 2026 | Trial primary completion date: Jul 2026 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
    1m
    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
    P2, N=23, Recruiting, University of California, Davis | Trial completion date: Dec 2026 --> May 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)
    |
    TNFRSF8 positive
    |
    Adcetris (brentuximab vedotin) • bendamustine
    1m
    ARCHED: Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=330, Recruiting, Universitt des Saarlandes | Trial primary completion date: Apr 2028 --> Feb 2029
    Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
    |
    Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisolone
    1m
    A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=60 --> 16
    Enrollment closed • Enrollment change
    |
    Rituxan (rituximab) • lenalidomide • Ezharmia (valemetostat)
    1m
    RHOA G17V mutation analysis redirecting diagnosis: nodal T-follicular helper cell lymphoma with classic Hodgkin lymphoma feature. (PubMed, J Clin Exp Hematop)
    The differential therapeutic response also supported a diagnosis of nTFHL, which could not have been established on morphology alone.In this case, although the HRS cells displayed morphological, immunophenotypic, and molecular features highly suggestive of CHL, the biological nature of the lesion was consistent with nTFHL. Compared with previously reported cases of nTFHL with HRS-like cells, this case more closely resembled CHL and may represent a distinct subset best described as "nTFHL with CHL features," a concept warranting greater recognition among pathologists and clinicians.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PAX5 (Paired Box 5) • IL2 (Interleukin 2) • RHOA (Ras homolog family member A)
    |
    PD-L1 expression • TNFRSF8 expression
    2ms
    Granulomatous cutaneous T-cell lymphoma in a patient with atage IVB of mycosis fungoides: a case report and literature review. (PubMed, Front Oncol)
    This report explores the clinical and histological manifestations of GMF, features distinguishing GMF from other granulomatous diseases, such as IGD, and the prognostic significance of distinguishing GMF from classic mycosis fungoides. We aimed to raise awareness among physicians regarding this rare disease and emphasize the characteristic histological features of GMF that can be confused with other types of mycosis fungoides.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule) • TRB (T Cell Receptor Beta Locus)
    2ms
    Digital and Manual Assessment of Intrafollicular Ki-67, MYC, and p53 in Classic Follicular Lymphoma. (PubMed, Diagnostics (Basel))
    These findings should be interpreted with caution in light of our limited cohort size. Strong concordance between manual and digital scoring supports the feasibility of digital IHC quantification in cFL.
    Journal
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    2ms
    FIL_FollVax22: Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance (clinicaltrials.gov)
    P=N/A, N=56, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Recruiting --> Active, not recruiting
    Enrollment closed